CureVac Secures €400M Upfront and Up to €1.05B in Milestones in New GSK Licensing Deal
Portfolio Pulse from Benzinga Newsdesk
GSK and CureVac have restructured their collaboration into a new licensing agreement, with GSK taking full control of developing and manufacturing mRNA vaccines. CureVac will receive €400M upfront and up to €1.05B in milestones. The agreement allows both companies to focus on their respective mRNA development activities.
July 03, 2024 | 6:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CureVac will receive €400M upfront and up to €1.05B in milestones from GSK under a new licensing agreement. CureVac retains rights to additional infectious disease targets and can independently develop mRNA vaccines.
The significant upfront payment and potential milestones from GSK provide CureVac with substantial financial resources. Retaining rights to additional targets allows CureVac to continue its mRNA vaccine development independently, which is likely to positively impact its stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100
POSITIVE IMPACT
GSK will take full control of developing and manufacturing mRNA vaccines under a new licensing agreement with CureVac. This move aligns with GSK's ongoing investment in vaccine platform technologies.
GSK's assumption of full control over mRNA vaccine development and manufacturing is a significant step in its strategic investment in vaccine technologies. This could positively impact GSK's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100